Clinical Trials
32 trialsDonor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Fred Hutchinson Cancer Center
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
University of Nebraska
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
Dartmouth-Hitchcock Medical Center
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Masonic Cancer Center, University of Minnesota
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
National Institutes of Health Clinical Center (CC)
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Stanford University
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
University of California, Davis
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Stanford University
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Bu Flu TBI
OHSU Knight Cancer Institute
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Fred Hutchinson Cancer Center
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
University of Rochester
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Indiana University
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center